Artichoke and Bergamot Phytosome

Artichoke and Bergamot Phytosome: a Randomized Double Blind Clinical Trial in Bergamot Poor-responders

According to WHO data, about 50% of deaths each year are caused by cardiovascular disease. One of the strategies for prevention of cardiovascular diseases, in addition to a correct lifestyle, is to implement therapies that reduce the level of cholesterol in the blood and at the same time control the glycemic levels, which are closely related in the maintenance of metabolic homeostasis. The aim of this clinical study is to confirm the potential broader activity as hypocholesterolemic agent in bergamot poor-responders subjects with mild hypercholesterolemia. The study was a 8-week randomized double-blind placebo-controlled trial. Participants were randomized to either the supplement based on dry extract from artichoke leaf and bergamot phospholipid (31) or placebo arm (29).

Inclusion Criteria:

• mild hypercholesterolemia (220 - 280 mg/dl)
• subjects were not taking any medication likely to affect lipid metabolism (such as statins)
• subjects were bergamot poor-responders

Exclusion Criteria:

• liver, renal and thyroid diseases
• history of cardiovascular disease (CVD)